Managers / Q1 2023 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Reported Value
$180M
Q1 2023
Positions
91
Filings on Record
25
2021–present window
Filed
May 15, 2023
original filing
Summary
Altium Capital Management LLC reported $180M in U.S.-listed holdings across 91 positions for Q1 2023.
Its largest position, Astria Therapeutics, represents 9.9% of the portfolio.
Compared with Q4 2022, the fund opened 34 new positions and exited 37.
Portfolio Metrics
Turnover
+39.6%
vs prior filed quarter
Top-10 Concentration
+39.8%
share of reported value
Largest Position
+9.9%
Astria Therapeutics
New / Exited
34 / 37
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 79.8% · $144M
- Other · 19.1% · $34M
- Equity WRT · 0.6% · $1M
- ADR · 0.5% · $987,790
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NOVOCURE LTD | NEW | +161.5K | 161.5K | +$10M | $10M |
| AVADEL PHARMACEUTICALS PLC | NEW | +500.0K | 500.0K | +$5M | $5M |
| PENPENUMBRA INC | NEW | +16.0K | 16.0K | +$4M | $4M |
| ATECALPHATEC HLDGS INC | NEW | +270.0K | 270.0K | +$4M | $4M |
| REATA PHARMACEUTICALS INC | NEW | +35.0K | 35.0K | +$3M | $3M |
| MERSANA THERAPEUTICS INC | NEW | +750.1K | 750.1K | +$3M | $3M |
| VREXVAREX IMAGING CORP | NEW | +165.0K | 165.0K | +$3M | $3M |
| INSPINSPIRE MED SYS INC | NEW | +12.5K | 12.5K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
80 positions (from 89 filing rows — )
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ASTRIA THERAPEUTICS INC | COM | 9.95% | $18M | 1.35M |
| 2 | ADMAADMA BIOLOGICS INChistory → | COM | 5.27% | $9M | 2.87M |
| 3 | BLUBELLUS HEALTH INC NEWhistory → | COM NEW | 4.52% | $8M | 1.13M |
| 4 | CHINOOK THERAPEUTICS INC | COM | 3.92% | $7M | 305.0K |
| 5 | AMLXAMYLYX PHARMACEUTICALS INChistory → | COM | 3.01% | $5M | 185.0K |
| 6 | CYMABAY THERAPEUTICS INC | COM | 3.00% | $5M | 620.0K |
| 7 | ARCELLX INC | COMMON STOCK | 2.57% | $5M | 150.0K |
| 8 | AVADEL PHARMACEUTICALS PLC | SPONSORED ADR | 2.54% | $5M | 500.0K |
| 9 | GKOSGLAUKOS CORPhistory → | COM | 2.53% | $5M | 91.0K |
| 10 | PENPENUMBRA INChistory → | COM | 2.48% | $4M | 16.0K |
| 11 | ATECALPHATEC HLDGS INChistory → | COM NEW | 2.34% | $4M | 270.0K |
| 12 | MYGNMYRIAD GENETICS INChistory → | COM | 2.32% | $4M | 180.0K |
| 13 | NEONEOGENOMICS INChistory → | COM NEW | 2.32% | $4M | 240.0K |
| 14 | AKOYA BIOSCIENCES INC | COM | 2.27% | $4M | 500.0K |
| 15 | XTNTXTANT MED HLDGS INChistory → | COM NEW | 2.20% | $4M | 6.23M |
| 16 | RMDRESMED INChistory → | COM | 2.07% | $4M | 17.0K |
| 17 | CTI BIOPHARMA CORP | COM | 1.98% | $4M | 850.0K |
| 18 | BHVNBIOHAVEN LTDhistory → | COM | 1.97% | $4M | 260.0K |
| 19 | REATA PHARMACEUTICALS INC | CL A | 1.77% | $3M | 35.0K |
| 20 | IVERIC BIO INC | COM | 1.76% | $3M | 130.0K |
| 21 | VREXVAREX IMAGING CORPhistory → | COM | 1.67% | $3M | 165.0K |
| 22 | INSPINSPIRE MED SYS INChistory → | COM | 1.62% | $3M | 12.5K |
| 23 | KRMDKORU MEDICAL SYSTEMS INChistory → | COM | 1.60% | $3M | 685.0K |
| 24 | REPLREPLIMUNE GROUP INChistory → | COM | 1.45% | $3M | 148.0K |
| 25 | BBIOBRIDGEBIO PHARMA INChistory → | COM | 1.43% | $3M | 155.0K |
| 26 | MDXGMIMEDX GROUP INChistory → | COM | 1.42% | $3M | 748.0K |
| 27 | NANOSTRING TECHNOLOGIES INC | COM | 1.24% | $2M | 226.0K |
| 28 | VERAVERA THERAPEUTICS INChistory → | CL A | 1.23% | $2M | 286.0K |
| 29 | ILMNILLUMINA INChistory → | COM | 1.16% | $2M | 9.0K |
| 30 | TG VENTURE ACQUISITION CORP | CLASS A COM · *W EXP 08/15/202 | 1.15% | $2M | 400.0K |
| 31 | PACBPACIFIC BIOSCIENCES CALIF INhistory → | COM | 1.14% | $2M | 178.0K |
| 32 | BIOLINERX LTD | SPONSORED ADS | 1.12% | $2M | 2.28M |
| 33 | KARYOPHARM THERAPEUTICS INC | COM | 1.09% | $2M | 505.8K |
| 34 | CVRXCVRX INChistory → | COM | 1.06% | $2M | 205.0K |
| 35 | VENTYX BIOSCIENCES INC | COM | 1.02% | $2M | 55.0K |
| 36 | DYNDYNE THERAPEUTICS INC | COM | 0.99% | $2M | 155.0K |
| 37 | SILK RD MED INC | COM | 0.98% | $2M | 45.0K |
| 38 | GENEDX HOLDINGS CORP | COM CL A | 0.93% | $2M | 4.59M |
| 39 | PCVXVAXCYTE INC | COM | 0.89% | $2M | 43.0K |
| 40 | CRNXCRINETICS PHARMACEUTICALS IN | COM | 0.89% | $2M | 100.0K |
| 41 | MARINUS PHARMACEUTICALS INC | COM NEW | 0.88% | $2M | 228.7K |
| 42 | AULT DISRUPTIVE TECHS CORP | COM | 0.87% | $2M | 150.0K |
| 43 | PEPPERLIME HEALTH ACQUSTN CO | CLASS A ORD SHS · *W EXP 10/01/202 | 0.58% | $1M | 467.5K |
| 44 | CYCUWWESTERN ACQSTN VENTURES CORP | COM · *W EXP 09/01/202 | 0.57% | $1M | 200.0K |
| 45 | THESEUS PHARMACEUTICALS INC | COM | 0.56% | $1M | 112.6K |
| 46 | HRMYHARMONY BIOSCIENCES HLDGS IN | COM | 0.54% | $979,500 | 30.0K |
| 47 | POLISHED COM INC | *W EXP 06/02/202 · COM | 0.50% | $903,271 | 6.68M |
| 48 | FAT BRANDS INC | *W EXP 07/16/202 | 0.50% | $896,650 | 227.0K |
| 49 | COLISEUM ACQUISITION CORP | CLASS A ORD SHS · *W EXP 08/22/202 | 0.49% | $876,208 | 113.3K |
| 50 | INVITAE CORP | COM | 0.31% | $552,420 | 409.2K |
| 51 | OPY ACQUISITION CORP I | COM CL A · *W EXP 09/22/202 | 0.29% | $520,415 | 100.0K |
| 52 | GSR II METEORA ACQUISITN COR | CLASS A COM · *W EXP 02/24/202 | 0.29% | $519,500 | 100.0K |
| 53 | COLOMBIER ACQUISITION CORP | CL A · *W EXP 99/99/999 | 0.28% | $510,105 | 66.7K |
| 54 | VRNAVERONA PHARMA PLC | SPONSORED ADS | 0.28% | $502,000 | 25.0K |
| 55 | DDIDOUBLEDOWN INTERACTIVE CO LT | ADS | 0.27% | $485,790 | 60.9K |
| 56 | CSSEQCHICKEN SOUP FOR THE SOUL EN | CL A | 0.24% | $424,328 | 212.2K |
| 57 | WEARABLE DEVICES LTD | *W EXP 09/14/202 | 0.11% | $193,672 | 1.41M |
| 58 | PANBELA THERAPEUTICS INC | COM NEW | 0.08% | $148,280 | 335.3K |
| 59 | DIRECT DIGITAL HOLDINGS INC | *W EXP 02/15/202 | 0.07% | $135,000 | 180.0K |
| 60 | JEFFS BRANDS LTD | *W EXP 08/26/202 | 0.06% | $106,058 | 980.8K |
| 61 | REVELATION BIOSCIENCES INC | COM NEW | 0.03% | $48,357 | 37.2K |
| 62 | HARBOR CUSTOM DEVELOPMENT IN | *W EXP 10/07/202 · *W EXP 05/09/202 | 0.03% | $46,895 | 1.25M |
| 63 | CINGWCINGULATE INC | *W EXP 12/10/202 | 0.03% | $46,197 | 270.0K |
| 64 | LUCYWINNOVATIVE EYEWEAR INC | *W EXP 08/16/202 | 0.02% | $44,768 | 122.4K |
| 65 | BRSWFBRUUSH ORAL CARE INC | *W EXP 08/03/202 | 0.02% | $43,269 | 360.6K |
| 66 | NXGLWNEXGEL INC | *W EXP 12/01/202 | 0.02% | $34,875 | 225.0K |
| 67 | NLS PHARMACEUTICS LTD | *W EXP 02/02/202 | 0.02% | $30,000 | 200.0K |
| 68 | ONFOWONFOLIO HOLDINGS INC | *W EXP 01/02/202 | 0.02% | $28,090 | 200.0K |
| 69 | PROSOMNUS INC | *W EXP 04/20/202 | 0.01% | $23,700 | 150.0K |
| 70 | BNCWWCEA INDUSTRIES INC | *W EXP 02/11/202 | 0.01% | $19,825 | 250.0K |
| 71 | LIGHTNING EMOTORS INC | *W EXP 05/18/202 | 0.01% | $16,630 | 652.2K |
| 72 | DIGITAL HEALTH ACQUISITION C | *W EXP 11/02/202 | 0.01% | $12,750 | 150.0K |
| 73 | SELINA HOSPITALITY PLC | *W EXP 10/27/202 | 0.01% | $10,144 | 101.4K |
| 74 | NEXALIN TECHNOLOGY INC | *W EXP 09/15/202 | 0.01% | $9,975 | 105.0K |
| 75 | MURPHY CANYON ACQUISITION CO | *W EXP 01/25/202 | 0.00% | $9,000 | 100.0K |
| 76 | SRZNWSURROZEN INC | *W EXP 08/01/203 | 0.00% | $8,223 | 82.2K |
| 77 | EUCRATES BIOMEDICAL ACQU COR | *W EXP 10/23/202 | 0.00% | $4,820 | 133.3K |
| 78 | CHAVANT CAPITAL ACQUISITN CO | *W EXP 99/99/999 | 0.00% | $4,710 | 150.0K |
| 79 | TCBWFTC BIOPHARM HOLDINGS PLC | *W EXP 02/08/202 | 0.00% | $1,880 | 18.8K |
| 80 | RELATIVITY ACQUISITION CORP | *W EXP 12/15/202 | 0.00% | $0 | 100.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $268M | 95 | May 5, 2021 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.